Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sansure BiotechSHSE:688289 -0.13%70 5-Year Yield-on-Cost % is 2.69 as of Aug. 26, 2026, which is 26% above its 10-year median of 2.14. GuruFocus rates SHSE:688289 with a GF Score™ of 70/100 and a GF Value™ of ¥21.49 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 315 Medical Devices & Instruments companies, Sansure Biotech ranks better than 53.02% on this metric.
Sansure Biotech's yield on cost for the quarter that ended in Mar. 2026 was 2.69.
The historical rank and industry rank for Sansure Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:688289'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.42 Med: 2.14 Max: 6.45
Current: 2.69
During the past 9 years, Sansure Biotech's highest Yield on Cost was 6.45. The lowest was 0.42. And the median was 2.14.
SHSE:688289's 5-Year Yield-on-Cost % is ranked better than 53.02% of 315
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs SHSE:688289: 2.69
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sansure Biotech 5-Year Yield-on-Cost % Related Terms
SHSE:688289 vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sansure Biotech is calculated as
Sansure Biotech (SHSE:688289) has a 5-Year Yield-on-Cost % of 2.69 as of Aug. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sansure Biotech and its competitors. This is 26% above median its historical median of 2.14. Over the past decade, Sansure Biotech's 5-Year Yield-on-Cost % has ranged from 0.42 to 6.45. According to the industry distribution chart, Sansure Biotech ranks #148 out of 315 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is Sansure Biotech's 5-Year Yield-on-Cost % too high?
Sansure Biotech's current 5-Year Yield-on-Cost % of 2.69 is 26% above median its 10-year median of 2.14. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 6.45. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.43. Sansure Biotech's value of 2.69 is 10.7% above this industry median. Based on the distribution chart, Sansure Biotech ranks #148 out of 315 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sansure Biotech has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #148 out of 315 companies for 5-Year Yield-on-Cost %. This puts Sansure Biotech in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Sansure Biotech's value of 2.69 is 10.7% above this benchmark. Historically, Sansure Biotech's own 5-Year Yield-on-Cost % has ranged from 0.42 to 6.45 over the past decade. While the company's 10-year median is 2.14 vs. the industry median of 2.43, Sansure Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current 5-Year Yield-on-Cost % of 2.69 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sansure Biotech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current 5-Year Yield-on-Cost % is 2.69, which is 26% above median its own 10-year median of 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.49, compared to a current price of ¥15.48 — trading 28% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.69, which is 26% above median its 10-year median of 2.14 and 10.7% above the Medical Devices & Instruments industry median of 2.43. Sansure Biotech's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current 5-Year Yield-on-Cost % is 2.69 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥15.48 is trading 28% below its estimated GF Value™ of ¥21.49.
GuruFocus considers Sansure Biotech to be Modestly Undervalued.
Key valuation signals for SHSE:688289:
5-Year Yield-on-Cost %: 2.69 (26% above median its 10-year median of 2.14)
GF Value™: ¥21.49 vs. price of ¥15.48 (28% below fair value)
Industry Position: 10.7% above the Medical Devices & Instruments median (#148 of 315)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
